Should I buy or sell Moleculin Biotech stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Moleculin Biotech in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MBRX shares. View MBRX analyst ratings or view top-rated stocks .

What is Moleculin Biotech's stock price target for 2024?

2 equities research analysts have issued 1-year price targets for Moleculin Biotech's stock. Their MBRX share price targets range from $5.00 to $16.00. On average, they predict the company's stock price to reach $10.50 in the next year. This suggests a possible upside of 1,621.3% from the stock's current price. View analysts price targets for MBRX or view top-rated stocks among Wall Street analysts .

How have MBRX shares performed in 2023?

Moleculin Biotech's stock was trading at $1.06 at the beginning of the year. Since then, MBRX stock has decreased by 42.5% and is now trading at $0.61. View the best growth stocks for 2023 here .

Are investors shorting Moleculin Biotech?

Moleculin Biotech saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 296,900 shares, an increase of 59.7% from the October 31st total of 185,900 shares. Based on an average daily trading volume, of 155,000 shares, the short-interest ratio is presently 1.9 days. View Moleculin Biotech's Short Interest .

When is Moleculin Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024. View our MBRX earnings forecast .

How were Moleculin Biotech's earnings last quarter?

Moleculin Biotech, Inc. (NASDAQ:MBRX) posted its earnings results on Friday, August, 11th. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.28) by $0.08. During the same period in the previous year, the company posted ($0.24) EPS.

When did Moleculin Biotech's stock split?

Moleculin Biotech shares reverse split on the morning of Monday, February 1st 2021. The 1-6 reverse split was announced on Friday, January 29th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 29th 2021. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

What other stocks do shareholders of Moleculin Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Moleculin Biotech investors own include Inovio Pharmaceuticals (INO) , Rite Aid (RAD) , VBI Vaccines (VBIV) , Gilead Sciences (GILD) , Novavax (NVAX) , Co-Diagnostics (CODX) , Dynavax Technologies (DVAX) , OPKO Health (OPK) , SCYNEXIS (SCYX) and Exelixis (EXEL) .

How do I buy shares of Moleculin Biotech?

Shares of MBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Moleculin Biotech Stock Price, News & Analysis (NASDAQ:MBRX)

$0.61

+0.01 (+1.67%)

(As of 12/1/2023 ET)

Compare

Today's Range: $0.58
▼
$0.61
50-Day Range: $0.40
▼
$0.62
52-Week Range: $0.34
▼
$1.65

Volume: 52,263 shs
Average Volume: 168,239 shs
Market Capitalization: $18.18 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.50

Moleculin Biotech MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,621.3% Upside
$10.50 Price Target
Short Interest: Healthy
1.00% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.29
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.88) to ($0.75) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.04 out of 5 stars

Medical Sector

567th out of 949 stocks

Pharmaceutical Preparations Industry

271st out of 442 stocks

3.5

Analyst's Opinion

Consensus Rating
Moleculin Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.50, Moleculin Biotech has a forecasted upside of 1,621.3% from its current price of $0.61.
Amount of Analyst Coverage
Moleculin Biotech has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.00% of the outstanding shares of Moleculin Biotech have been sold short.
Short Interest Ratio / Days to Cover
Moleculin Biotech has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Moleculin Biotech has recently increased by 59.71%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Moleculin Biotech does not currently pay a dividend.
Dividend Growth
Moleculin Biotech does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MBRX.

2.4

News and Social Media Coverage

News Sentiment
Moleculin Biotech has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Moleculin Biotech this week, compared to 1 article on an average week.
Search Interest
2 people have searched for MBRX on MarketBeat in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Moleculin Biotech insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.70% of the stock of Moleculin Biotech is held by insiders.
Percentage Held by Institutions
Only 7.67% of the stock of Moleculin Biotech is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Moleculin Biotech are expected to grow in the coming year, from ($0.88) to ($0.75) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Moleculin Biotech is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Moleculin Biotech is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Moleculin Biotech has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Moleculin Biotech Stock (NASDAQ:MBRX)

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas.

MBRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MBRX Stock News Headlines

December 1, 2023 | markets.businessinsider.com

Oppenheimer Keeps Their Buy Rating on Moleculin Biotech (MBRX)

November 29, 2023 | americanbankingnews.com

Moleculin Biotech (NASDAQ:MBRX) Research Coverage Started at StockNews.com

December 1, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 21, 2023 | americanbankingnews.com

Moleculin Biotech (NASDAQ:MBRX) Coverage Initiated by Analysts at StockNews.com

November 14, 2023 | finance.yahoo.com

Moleculin Biotech, Inc. (NASDAQ:MBRX) Q3 2023 Earnings Call Transcript

November 13, 2023 | msn.com

Moleculin Biotech gains after early data for lead cancer therapy

November 13, 2023 | finanznachrichten.de

Moleculin Biotech, Inc.: Moleculin Reports Third Quarter 2023 Financial Results

November 13, 2023 | msn.com

Moleculin Biotech Q3 GAAP EPS of -$0.19 beats by $0.03

December 1, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 13, 2023 | markets.businessinsider.com

Moleculin Biotech Announces Positive Interim Data For Annamycin Trials

November 13, 2023 | benzinga.com

Penny Stock Moleculin Highlights Interim Data From Blood Cancer Study With Complete Response Rate of 38%

November 13, 2023 | finance.yahoo.com

Moleculin Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months

November 13, 2023 | finance.yahoo.com

Moleculin Reports Third Quarter 2023 Financial Results

November 10, 2023 | msn.com

Moleculin Biotech Q3 2023 Earnings Preview

November 8, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Scholar Rock Holding (SRRK) and Moleculin Biotech (MBRX)

November 7, 2023 | finance.yahoo.com

Moleculin to Report Third Quarter Financial Results on November 13, 2023 and Host Conference Call and Webcast

November 6, 2023 | finance.yahoo.com

Moleculin Presents Positive Preliminary Efficacy Findings from Phase 1B/2 Clinical Trial Demonstrating 64% Stable Disease Rate Through Two Cycles of Annamycin for the Treatment of Soft Tissue Sarcomas (STS) Lung Metastases

October 11, 2023 | finance.yahoo.com

Moleculin to Participate in the Virtual Investor Ask the CEO Conference

October 2, 2023 | finance.yahoo.com

Moleculin Doses First Subjects in Phase 2 Portion of Clinical Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)

September 21, 2023 | finance.yahoo.com

Moleculin Announces Completion of Enrollment in U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB107)

September 18, 2023 | markets.businessinsider.com

Moleculin Biotech Reports Independent Report Of No Cardiotoxicity In Annamycin

September 18, 2023 | finance.yahoo.com

Moleculin Announces New Positive Independent Report of No Cardiotoxicity in Annamycin

September 15, 2023 | investorplace.com

Why Is Moleculin Biotech (MBRX) Stock Is Moving Today?

September 14, 2023 | finance.yahoo.com

Moleculin Announces Abstract Accepted for Poster Presentation at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting

September 5, 2023 | finance.yahoo.com

Moleculin to Present at the H.C. Wainwright 25th Annual Global Investment Conference

August 12, 2023 | markets.businessinsider.com

Maxim Group Sticks to Their Buy Rating for Moleculin Biotech (MBRX)

August 12, 2023 | finance.yahoo.com

Q2 2023 Moleculin Biotech Inc Earnings Call

See More Headlines

Receive MBRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Moleculin Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/11/2023
Today: 12/01/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/27/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:MBRX
CUSIP: N/A
CIK: 1659617
Web: www.moleculin.com
Phone: (713) 300-5160
Fax: N/A
Employees: 15
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $10.50
High Stock Price Target: $16.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +1,621.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.91)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-29,020,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -60.64%
Return on Assets: -53.85%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.10
Quick Ratio: 7.10

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.18 per share
Price / Book: 0.52

Miscellaneous

Outstanding Shares: 29,810,000
Free Float: 27,813,000
Market Cap: $18.18 million
Optionable: Not Optionable
Beta: 1.89

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Mr. Walter V. Klemp (Age 63)
Founder, Chairman, President & CEO
Comp: $1.35M
Mr. Jonathan P. Foster CPA (Age 59)
Executive VP & CFO
Comp: $653.69k
Dr. Donald H. Picker Ph.D. (Age 77)
Chief Scientific Officer
Comp: $520.84k
Dr. Waldemar Priebe Ph.D.
Co-Founder, Founding Scientist & Chairman of Scientific Advisory Board
Dr. Robert C. Shepard FACP (Age 71)
M.D., Chief Medical Officer of Annamycin
Dr. John Paul Waymack M.D. (Age 71)
Sc.D., Senior Chief Medical Officer
Dr. Sandra L. Silberman M.D. (Age 68)
Ph.D., Chief Medical Officer of New Products
Dr. Wolfram C. M. Dempke M.B.A.
M.D., Ph.D., European Chief Medical Officer
Ms. Jacqueline Northcut (Age 61)
Consultant
Comp: $51.11k
Mr. Louis Ploth Jr. (Age 69)
Independent Advisor
Comp: $118.49k

Key Competitors

View All Competitors

MBRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Moleculin Biotech stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Moleculin Biotech in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MBRX shares.
View MBRX analyst ratings or view top-rated stocks.
What is Moleculin Biotech's stock price target for 2024?: 2 equities research analysts have issued 1-year price targets for Moleculin Biotech's stock. Their MBRX share price targets range from $5.00 to $16.00. On average, they predict the company's stock price to reach $10.50 in the next year. This suggests a possible upside of 1,621.3% from the stock's current price.
View analysts price targets for MBRX or view top-rated stocks among Wall Street analysts.
How have MBRX shares performed in 2023?: Moleculin Biotech's stock was trading at $1.06 at the beginning of the year. Since then, MBRX stock has decreased by 42.5% and is now trading at $0.61.
View the best growth stocks for 2023 here.
Are investors shorting Moleculin Biotech?: Moleculin Biotech saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 296,900 shares, an increase of 59.7% from the October 31st total of 185,900 shares. Based on an average daily trading volume, of 155,000 shares, the short-interest ratio is presently 1.9 days.
View Moleculin Biotech's Short Interest.
When is Moleculin Biotech's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024.
View our MBRX earnings forecast.

How were Moleculin Biotech's earnings last quarter?: Moleculin Biotech, Inc. (NASDAQ:MBRX) posted its earnings results on Friday, August, 11th. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.28) by $0.08. During the same period in the previous year, the company posted ($0.24) EPS.
When did Moleculin Biotech's stock split?: Moleculin Biotech shares reverse split on the morning of Monday, February 1st 2021. The 1-6 reverse split was announced on Friday, January 29th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 29th 2021. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.
What other stocks do shareholders of Moleculin Biotech own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Moleculin Biotech investors own include Inovio Pharmaceuticals (INO), Rite Aid (RAD), VBI Vaccines (VBIV), Gilead Sciences (GILD), Novavax (NVAX), Co-Diagnostics (CODX), Dynavax Technologies (DVAX), OPKO Health (OPK), SCYNEXIS (SCYX) and Exelixis (EXEL).
How do I buy shares of Moleculin Biotech?: Shares of MBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:MBRX) was last updated on 12/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial